Sentigen Holding Corp. Announces Second Quarter Results

Sentigen Holding Corp. (Nasdaq: SGHL), today reported
results for the quarter and six months ended June 30, 2006. Sentigen
Holding Corp. conducts business through two wholly-owned operating
subsidiaries: Sentigen Biosciences, Inc. ("Sentigen Biosciences") and
Cell & Molecular Technologies, Inc. ("CMT").

   Consolidated Results of Continuing Operations

   Revenues for the three months ended June 30, 2006 were $973,869 a
43% decrease over the revenues of $1,700,199 for the three months
ended June 30, 2005. Our revenues are primarily attributed to CMT,
which accounted for $778,964 of our consolidated revenues for the
three months ended June 30, 2006 and a 48% decrease when compared to
CMT's revenues for the three months ended June 30, 2005. The remainder
of the revenue on a consolidated basis was due to Sentigen
Biosciences' contract with the Technical Support Working Group
("TSWG") which accounted for $194,905 of revenue for the three months
ended June 30, 2006. In May 2006, Sentigen Biosciences reached a
conclusion to the research objectives under its contract with TSWG and
funding ended in June 2006.
   Revenues for the six months ended June 30, 2006 were $2,297,623, a
34% decrease over the $3,461,715 of revenues for the six months ended
June 30, 2005. CMT accounted for $1,660,055 of our consolidated
revenues for the six months ended June 30, 2006 and a 47% decrease
when compared to CMT's revenues for the six months ended June 30,
2005. The remainder of the revenues on a consolidated basis was
primarily due to Sentigen Biosciences' contract with TSWG which
accounted for $453,569 of revenue for the six months ended June 30,
2006.
   The loss from continuing operations for the three months ended
June 30, 2006 was $880,990 or $0.12 per share. This compares to a loss
from continuing operations of $655,428 or $0.09 per share for the
three months ended June 30, 2005. The increase in loss was primarily
due to a decrease in the income from continuing operations of CMT
offset by reductions in selling, general and administrative costs and
research and development expenses.
   The loss from continuing operations for the six months ended June
30, 2006 was $1,559,478 or $0.21 per share. This compares to a loss
from continuing operations of $1,206,659 or $0.16 per share for the
six months ended June 30, 2005. The increase in loss was primarily due
to the decline in revenues for the six months ended June 30, 2006,
offset by decreases in operating expenses as compared to the six
months ended June 30, 2005.

   Results of Continuing Operations by Segment

   Cell & Molecular Technologies, Inc. Income from continuing
operations attributable to CMT for the three months ended June 30,
2006 decreased 220% to a loss of $280,222. This is in comparison to
income of $233,187 for the three months ended June 30, 2005. Income
from continuing operations attributable to CMT for the six months
ended June 30, 2006 decreased by 183% from $530,137 for the six months
ended June 30, 2005 to a loss of $440,144. The decrease was primarily
driven by CMT's decreased revenues.
   Sentigen Biosciences. Loss from continuing operations attributable
to Sentigen Biosciences for the three months ended June 30, 2006 was
$284,165, a 38% reduction when compared to the loss from operations of
$455,601 for the three months ended June 30, 2005. Loss from
continuing operations attributable to Sentigen Biosciences for the six
months ended June 30, 2006 was $368,510, a 56% improvement when
compared to the loss from operations of $836,474 for the six months
ended June 30, 2005. The reduction in loss was primarily due to the
decrease in research and development costs.
   Corporate. Loss from continuing operations attributable to
corporate holding company expenses for the three months ended June 30,
2006 was $396,227. This compares to a loss attributable to corporate
holding company expenses of $504,489 for the three months ended June
30, 2005, a reduction of 21%. The decrease was primarily due to
decreased compensation and commercial insurance expenses, offset by
increased professional legal and public company expenses. Loss from
continuing operations attributable to corporate holding company
expenses for the six months ended June 30, 2006 was $916,022. This
compares to a loss attributable to corporate holding company expenses
of $1,044,876 for the six months ended June 30, 2005, a reduction of
12%. The reduction was primarily due to a decline in rent, commercial
insurance, salaries and professional fees.

   Cash and Working Capital

   At June 30, 2006, we had $253,264 in cash and cash equivalents,
$11,461,828 in U.S. Treasury Notes at market value, and $10,791,185 in
working capital. This compares to $106,622 in cash and cash
equivalents, $13,378,020 in U.S. Treasury Notes, at market value, and
$11,846,492 in working capital at December 31, 2005. It should be
noted that we will need substantial amounts of additional financing to
commercialize the research programs undertaken by us. We cannot give
any assurances that this additional financing will be available to us
on reasonable terms, if at all.
   On February 22, 2005, we sold Specialty Media, a division of CMT,
for $6.5 million. Accordingly, the assets and liabilities of Specialty
Media were disposed as of February 22, 2005 in our balance sheets. In
addition, the statements of operations for Specialty Media have been
accounted for as discontinued operations in our consolidated
statements of operations.

-0-
*T

                SENTIGEN HOLDING CORP. AND SUBSIDIARIES
                         FINANCIAL HIGHLIGHTS


Income statement highlights:
----------------------------

                          (Unaudited)               (Unaudited)
                            For the                   For the
                      Three Months Ended         Six Months Ended
                           June 30,                  June 30,
                   ------------------------- -------------------------
                       2006         2005         2006         2005
                   ------------ ------------ ------------ ------------
Revenue
  CMT              $   778,964  $ 1,509,026  $ 1,660,055  $ 3,106,730
  Sentigen
   Biosciences         194,905      191,173      637,568      354,985
                    -----------  -----------  -----------  -----------
                       973,869    1,700,199    2,297,623    3,461,715

Income after
 direct costs
  CMT                  295,052      928,728      758,948    1,925,829
  Sentigen
   Biosciences          60,281       79,639      326,349      143,689
                    -----------  -----------  -----------  -----------
                       355,333    1,008,367    1,085,297    2,069,518
Operating
 (loss)/income
  CMT                 (280,222)     233,187     (440,144)     530,137
  Sentigen
   Biosciences        (284,165)    (455,601)    (368,510)    (836,474)
  Corporate           (396,227)    (504,489)    (916,022)  (1,044,876)
                    -----------  -----------  -----------  -----------

Operating (loss)      (960,614)    (726,903)  (1,724,676)  (1,351,213)
                    -----------  -----------  -----------  -----------

Loss from
 continuing
 operations           (880,990)    (655,428)  (1,559,478)  (1,206,659)


(Loss)/income from
 discontinued
 operations, net
 of tax (including
 gain on disposal
 of $4,773,810,
 net of tax of
 $889,209 for the
 six months ended
 June 30, 2005               -      (88,200)           -    4,835,122
                    -----------  -----------  -----------  -----------

Net (loss)/income  $  (880,990) $  (743,628) $(1,559,478) $ 3,628,463
                   ============ ============ ============ ============

Net income (loss)
 per share information:
-----------------------

Basic and diluted
 loss per share
 from continuing
 operations        $     (0.12) $     (0.09) $     (0.21) $     (0.16)
                   ============ ============ ============ ============


Basic and diluted
 net (loss) income
 per share from
 discontinued
 operations        $         -  $     (0.01) $         -  $      0.65
                   ============ ============ ============ ============

Basic and diluted
 net (loss) income
 per share         $     (0.12) $     (0.10) $     (0.21) $      0.49
                   ============ ============ ============ ============

Weighted average
 shares
 outstanding:
   Basic and
    Diluted          7,624,620    7,473,117    7,551,081    7,472,309
                   ============ ============ ============ ============

Balance Sheet Highlights:                    
-------------------------                    

                                             (Unaudited)
                                               June 30,   December 31,
                                                 2006         2005
                                             ------------ ------------
Cash and cash equivalents                    $   253,264  $   106,622
U.S. treasury notes                           11,461,828   13,378,020
Total current assets                          12,637,016   14,531,489
Total assets                                  13,499,103   15,600,243

Current maturities of long term debt         $   204,637  $   191,383
Current liabilities                            1,845,831    2,684,997
Long-term debt                                   537,255      644,490
Total liabilities                              2,383,086    3,336,407

Stockholder's Equity                         $11,116,017  $12,263,836

*T

   Forward Looking Statements

   This news release includes forward-looking statements that involve
risks and uncertainties. Although the Company believes such statements
are reasonable, it can make no assurance that such statements will
prove to be correct. Such statements are subject to certain factors
that may cause results to differ materially from the forward-looking
statements. Such factors include the risk factors discussed in the
Company's filings with the Securities and Exchange Commission,
including its most recent Annual Report on Form 10-K, a copy of which
may be obtained from the Company without charge. The Company
undertakes no obligation to publicly release results of any of these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unexpected results.

   About Sentigen Holding Corp.

   Sentigen Holding Corp. conducts business through two wholly-owned
operating subsidiaries: Sentigen Biosciences, Inc. ("Sentigen
Biosciences") and Cell & Molecular Technologies, Inc. ("CMT").
   CMT provides contract research and development services to
companies engaged in the drug discovery process in the following
areas: molecular and cell biology, gene expression and protein
biochemistry, bio-processing, high throughput screening support
services, mouse genetics, and cell-based GPCR selectivity profiling.
CMT works in cooperation with Sentigen Biosciences to commercialize
specific applications of the Tango(TM) Assay System.
   Sentigen Biosciences has been primarily engaged in the development
and commercialization of novel bioassay systems that elucidate the
underlying biology of protein-protein interactions. Sentigen
Biosciences has initially targeted its Tango(TM) Assay System to
address the functionalization of G protein-coupled receptors (GPCRs)
for pharmaceutical drug discovery and development. Sentigen
Biosciences is devoting a significant portion of its research effort
and resources to the development of a novel molecular profiling
system, which the Company through CMT is commercializing. Management
intends to continually review the commercial validity of the Tango(TM)
Assay System, its applicability to functionalizing orphan GPCRs and
the prospects of our new novel molecular profiling system in order to
make the appropriate decisions as to the best way to allocate our
limited resources. While we believe our technology capabilities in the
bioscience area are substantial, up to this point, Sentigen
Biosciences has incurred substantial operating losses. Although we
have completed several pilot research collaborations, we have not
entered into any drug discovery or development agreements, nor can any
assurance be given that we will be able to do so on terms that are
acceptable to us.

   For more information on our companies, please visit their
respective websites: http://www.cmt-inc.net and
http://www.sentigen.com.